If you are interested to learn more about these projects, contact us.
- Oncology Chromosomal instability is a hallmark of cancer cells. Enhancing chromosomal instability by targeting the mitotic checkpoint selectively kills tumor cells. NTRC has developed best-in-class inhibitors of the mitotic checkpoint kinase TTK. The protein kinase TTK (commonly referred to as Mps1) is a component of the mitotic checkpoint, a machinery that ensures the fidelity of sister chromatid ... Read more
- Autoimmune disease Aberrant functioning of T lymphocytes is the basis of autoimmune disease and T cell leukaemia. NTRC scientists have developed a series of highly selective inhibitors of T cell activity. T lymphocytes are a critical component of the acquired immune system, while aberrant T cell functioning is the basis of autoimmune diseases, such as rheumatoid arthritis and ... Read more
- Parkinson’s disease Tryptophan dioxygenase is a promising new drug target for neurodegenerative disease, including Parkinson’s disease. NTRC has developed a proprietary assay technology for high-throughput screening of tryptophan catabolizing enzymes. Tryptophan is an essential amino acid that is used for protein synthesis and the production of neurotransmitters that regulate behaviour, such as serotonin and melatonin. Aberrant tryptophan catabolism ... Read more